Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy

Hu, Chen; Ma, Qiang; Li, Nengsheng; Luo, Nuo; Hao, Shuai; Jiang, Minrui; Pang, Fei; Yang, Yan; Li, Li; He, Yong

doi:10.3389/fonc.2021.693704

Cited by 4 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Furthermore, 'real-world evidence' on neoadjuvant immuno(chemo)therapy in oligometastatic patients is restricted to few cases reporting encouraging outcome. [26][27][28] To assess the efficacy of neoadjuvant immuno(chemo)therapy in a broad real-world NSCLC population, we performed a multicentre retrospective analysis (KOMPASSneoOP) of pathological and radiological response and survival after resection following neoadjuvant immuno(chemo)therapy in patients with stage IIB-IVB NSCLC (oligometastatic). 5 Furthermore, we addressed the open question of the necessary number of cycles of neoadjuvant therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)

et al. 2022

View full text Add to dashboard Cite

Background: Recent clinical trials demonstrate the feasibility of neoadjuvant immuno(chemo)therapy and report high rates of pathological remission, a surrogate marker for overall survival. Patients and methods: This is a retrospective multicentre real-world analysis of patients with locally resectable NSCLC, including oligometastatic disease, who received neoadjuvant immuno(chemo)therapy and resection. Consolidating immunotherapy was applied following multidisciplinary board recommendation. Primary endpoint was the rate of complete pathological response (pCR, no residual vital tumour cells) or major pathological response (MPR, ⩽ 10% residual vital tumour cells). Secondary endpoints included the radiological response and survival. Results: Seven centres contributed 59 patients (56% stage IIB–IIIC, 44% in stage IVA–IVB with up to four oligometastatic sites). MPR was found in 68% including 53% with pCR. There were no radiological progressions. Median follow-up was 24.3 months. At 12 and 24 months, progression-free survival was 82.6% and 68.1%, and overall survival was 89.5% and 87.2%, respectively. Conclusion: To our knowledge, this study encompassed the largest NSCLC real-world cohort treated with neoadjuvant immuno(chemo)therapy to date. In routine clinical practice, resection after neoadjuvant immuno(chemo)therapy is feasible in patients with locally resectable NSCLC, including oligometastatic disease. In line with clinical trials, we found MPR in more than two-thirds of patients. Early data show encouraging survival.

show abstract

Section: Introductionmentioning

confidence: 99%

“…25 Furthermore, ‘real-world evidence’ on neoadjuvant immuno(chemo)therapy in oligometastatic patients is restricted to few cases reporting encouraging outcome. 26 –28…”

Section: Introductionmentioning

confidence: 99%

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this case, what was surprising was that the patient presented with MSS and negative PD-L1 expression who was supposed to be relatively insensitive to immunotherapy and found that she still had an excellent response to anti-PD-1 antibody combined with chemotherapy, indicating that other mechanisms than MSI and PD-L1 positive might account for the responsiveness to ICIs (28). As shown in Table 1, this phenomenon has also been reported in gallbladder carcinoma (14), leiomyosarcoma (15), non-small cell lung cancer (21), gastroesophageal junction carcinoma (28), melanoma (32), and small cell lung cancer (37). Previous studies demonstrated that chemotherapy might be able to enhance anticancer immunity by reactivating immune effector cells, stimulating tumor antigen presentation, and eliminating immune suppressor cells, thus resulting in a synergistic anticancer effect compared with the anti-PD-1 monotherapy (58,59).…”

Section: Discussionmentioning

confidence: 69%

Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: A rare case report and literature review

et al. 2023

View full text Add to dashboard Cite

BackgroundHepatoid adenocarcinoma of the stomach (HAS) is a highly malignant subtype of gastric carcinoma with specific clinicopathological features and extremely poor prognosis. We present an exceedingly rare case of complete response after chemo-immunotherapy.Case DescriptionA 48-year-old woman with highly elevated serum alpha-fetoprotein (AFP) level was found to have HAS verified by pathological examination based on gastroscopy. Computed tomography scan was done and TNM staging of the tumor was T4aN3aMx. Programmed cell death ligand-1 (PD-L1) immunohistochemistry was performed, revealing a negative PD-L1 expression. Chemo-immunotherapy including oxaliplatin plus S-1 and PD-1 inhibitor terelizumab was given to this patient for 2 months until the serum AFP level decreased from 748.5 to 12.9 ng/mL and the tumor shrank. D2 radical gastrectomy was then performed and histopathology of the resected specimen revealed that the cancerous cells had disappeared. Pathologic complete response (pCR) was achieved and no evidence of recurrence has been found after 1 year of follow-up.ConclusionsWe, for the first time, reported an HAS patient with negative PD-L1 expression who achieved pCR from the combined chemotherapy and immunotherapy. Although no consensus has been reached regarding the therapy, it might provide a potential effective management strategy for HAS patient.

show abstract

“…As such, an increasing number of cancer patients have benefitted from immunotherapy. [ 2 , 3 ] In recent years, great achievements have been made regarding immune checkpoint inhibitors in research on neoadjuvant immunotherapy. Among them, nivolumab's performance has been particularly eye-catching, bringing significant clinical benefits to some patients with early and middle stage tumors, and becoming a hot topic in the field of cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Some programmed death-1 (PD-1)/programmed death receptor ligand-1 (PDL-1) inhibitors can activate the autoimmune system and inhibit tumor progression. As such, an increasing number of cancer patients have benefitted from immunotherapy [2,3] . In recent years, great achievements have been made regarding immune checkpoint inhibitors in research on neoadjuvant immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy

Li¹,

Chen²,

Lai³

et al. 2022

Medicine

View full text Add to dashboard Cite

Rationale: For locally advanced non-small cell lung cancer (NSCLC), the neoadjuvant therapy strategy of preoperative nivolumab combined with chemotherapy has great potential, especially for locally advanced NSCLC which are initially unresectable. They may be cured after neoadjuvant immunotherapy, and this may become a new direction of treatment. We hope that this representative medical record and literature review can provide some assistance for clinicians using immune checkpoint inhibitors to treat lung cancer. Patient concerns: A 50-year-old male patient was admitted to Zhongshan Hospital of Traditional Chinese Medicine on April 27, 2020 due to “coughing for more than one month.”. The patient had nothing of note in either his medical history or that of his family, and no history of smoking. Diagnosis: The diagnosis was cT4N2M0IIIB stage right lower lung NSCLC with right hilar and mediastinal lymph node metastasis. The stage was inoperable stage IIIB NSCLC, but the patient had a strong willingness for doing surgery. Interventions: The patient received 3 rounds of the neoadjuvant nivolumab therapy combined with TP (paclitaxel plus cisplatin) regimen, on 5-14-21, 06-07-21 and 07-07-21. Outcomes: The tumor's area shrunk. Then the patient underwent thoracoscopic radical resection of the cancer in the right upper lung and postoperative pathology achieved pathological complete response (pCR) Lessons: In this case, combined with the wishes of the patient and the latest research results, we confirmed pCR by radical surgery after 3 rounds of the neoadjuvant nivolumab therapy combined with chemotherapy. This may be a modality to cure more lung cancer patients in the future.

show abstract

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy

Cited by 4 publications

References 15 publications

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)

Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: A rare case report and literature review

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy

Contact Info

Product

Resources

About